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Abstract
Melanoma is the most fatal skin cancer, but the etiology of this devastating disease is still
poorly understood. Recently, the transcription factor Sox10 has been shown to promote
both melanoma initiation and progression. Reducing SOX10 expression levels in human
melanoma cells and in a genetic melanoma mouse model, efficiently abolishes tumorigene-
sis by inducing cell cycle exit and apoptosis. Here, we show that this anti-tumorigenic effect
functionally involves SOX9, a factor related to SOX10 and upregulated in melanoma cells
upon loss of SOX10. Unlike SOX10, SOX9 is not required for normal melanocyte stem cell
function, the formation of hyperplastic lesions, and melanoma initiation. To the contrary,
SOX9 overexpression results in cell cycle arrest, apoptosis, and a gene expression profile
shared by melanoma cells with reduced SOX10 expression. Moreover, SOX9 binds to the
SOX10 promoter and induces downregulation of SOX10 expression, revealing a feedback
loop reinforcing the SOX10 low/SOX9 high ant,m/ii-tumorigenic program. Finally, SOX9 is
required in vitro and in vivo for the anti-tumorigenic effect achieved by reducing SOX10 ex-
pression. Thus, SOX10 and SOX9 are functionally antagonistic regulators of
melanoma development.
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Author Summary
For the development of future cancer therapies it is imperative to understand the molecu-
lar processes underlying tumor initiation and expansion. Many key factors involved in
these processes have been identified based on cell culture and transplantation experiments,
but their relevance for tumor formation and disease progression in the living organism is
often unclear. Therefore, genetically modified mice spontaneously developing tumors
present indispensable models for cancer research. Here, we address this issue by studying
the formation of melanoma, the most fatal skin tumor in industrialized countries. To this
end, we use a transgenic mouse model to elucidate cellular and molecular mechanisms reg-
ulating congenital nevus and melanoma initiation. We show that a transcription factor
called SOX10 promotes melanoma formation by repressing an anti-tumorigenic program
involving the activity of a related factor, SOX9. When SOX10 is inactivated, SOX9 be-
comes upregulated and induces cell cycle arrest and death in melanoma cells. Further-
more, upon experimental elevation of SOX9 levels, SOX10 activity is suppressed, revealing
an antagonistic relationship between SOX9 and SOX10 in melanoma initiation. Knowl-
edge of how an anti-tumorigenic program can be stimulated by modulating the activities
of these key factors might help to design novel therapeutic strategies.
Introduction
Sox (Sry (sex determining region Y)-related HMG box) genes encode a family of transcription
factors that are characterized by a conserved high-mobility group (HMG) domain mediating
their binding to DNA in a sequence-specific manner [1–3]. While the majority of Sox proteins
functions as transcriptional activators, some members of the Sox family including Sox9 and
Sox10 may also act as transcriptional repressors [4–6]. Sox genes play key roles in embryonic
development and are major determinants of stem cell behavior, regulating cell fate decisions
and maintaining cellular identity [3]. Their crucial role in normal tissue formation and homeo-
stasis is evident from the fact that several mutations in Sox genes are causative for developmen-
tal diseases, and accumulating evidence demonstrates the important functional role of Sox
family proteins in a variety of cancers [7–10].
A common feature of SoxE group proteins, which includes Sox9 and Sox10, is their expres-
sion in neural crest (NC) cells during embryonic development [2, 11]. NC cells are a transient
embryonic cell population that gives rise to most of the peripheral nervous system, chondro-
cytes and osteoblasts of craniofacial structures, smooth muscle cells of the cardiovascular sys-
tem, and melanocytes, the pigmented cells of the skin [12]. While Sox9 is expressed in
premigratory NC cells and in the pharyngeal apparatus, Sox10 is found in NC cells at the time
of their emigration and is essential for their self-renewal and survival [12–16]. Loss of Sox10 re-
sults in absence of most NC derivatives, whereas Sox10 haploinsufficiency causes Waardenburg
Hirschsprung syndrome, characterized by aganglionic megacolon, pigmentary abnormalities
and often deafness due to loss of sensory innervation [13, 17–20]. In the melanocytic lineage,
Sox10 is expressed during all stages of development as well as in the adult and is required in dif-
ferent species for the generation and homeostasis of embryonic and adult melanocytes in vitro
and in vivo [13, 21–25].
In contrast, loss of Sox9 in the NC does not lead to general defects in NC-derived structures,
but specifically affects the development of mesectodermal derivatives, such as smooth muscle
cells and craniofacial bones and cartilage [11, 26–28]. Furthermore, heterozygous mutations in
Sox9 in both mice and humans, result in campomelic dysplasia, a syndrome associated with
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dwarfism, skeletal malformations, cleft palate, XY sex reversal and often hermaphroditism
[28–30]. However, data on Sox9 expression in melanocytes are inconsistent, and a functional
implication of Sox9 in melanocyte formation has not been provided so far [23].
Based on the assumption that mechanisms of tumor formation might be related to those
underlying the generation of the cell type, from which the tumor develops, we and others have
recently addressed the function of Sox10 in melanoma. These studies demonstrated a crucial
role of Sox10 in the pathogenesis of giant congenital naevi and melanoma in both mice and hu-
mans by regulating proliferation and survival of melanocytic cells and maintenance of their
cellular identity [9; 31]. However, the precise molecular mechanisms mediating Sox10 function
in melanoma remain to be investigated.
Here we show that in contrast to Sox10, Sox9 appears to be expressed at very low levels only
and is functionally not required in melanocyte stem cells, committed melanocytes, and mela-
noma cells. However, Sox9 expression is elevated upon Sox10 deletion in mouse and human
melanoma cells [9], and critically contributes to the anti-tumorigenic effects observed upon
Sox10 inactivation in giant congenital naevus and melanoma.
Results
Expression analysis of SOXE factors in human skin melanocytes, giant
congenital naevi, and primary melanoma in vivo
While SOX10 expression and function has been well established in adult melanocytes, naevi,
and melanoma tissue in human and mice [9; 23], studies on SOX9 expression in melanocytic
cells are controversial. SOX9 was reported to be expressed in cultured human melanocytes
in vitro [32], human melanocytes in vivo [33], and in human melanoma [34–36]. Other re-
ports, however, failed to reveal Sox9 mRNA and protein expression in melanoblasts and differ-
entiated melanocytes during development and postnatally [21,37]. Given the close relationship
between SoxE factors, one conceivable explanation for these discrepancies might be that
antibodies raised against a given SoxE protein fail to discriminate between SOX9 and SOX10
epitopes. Indeed, when we performed immunohistochemistry on murine skin to test the
specificity of various anti-SOX9 antibodies, several of them recognized both melanocytes and
epithelial cells in the outer root sheet (a region in hair follicles known to express and function-
ally require Sox9; [37–38] (S1 Fig.). In contrast, the antibody sc-20095 exclusively detected pro-
tein expression in epithelial cells but not in melanocytes. Of note, in human melanoma cell
lines in vitro, all antibodies tested but sc-20095 not only recognized SOX9, but also a protein of
the molecular weight of SOX10 and detected by a SOX10-specific antibody (S2A-S2D Fig.).
To further investigate the specificity of anti-SOX9 antibodies, we performed SOX10 knock-
down in human melanoma cell lines in vitro and analyzed SOX10 and SOX9 expression using
Western blot analysis (S2E-S2K Fig.). As shown in S2E-S2K Fig., different anti-SOX9 antibod-
ies used in earlier studies detected SOX10 protein expression, which was lost upon SOX10
knock-down. The only anti-SOX9 antibody, which did not display cross-reactivity with SOX10
protein, was sc-20095.
Therefore, we chose to reassess SOX9 expression in human melanocytes and melanocytic
skin lesions using the specific SOX9 antibody sc-20095. Double immunostaining for SOX9 and
MITF (Microphthalmia-associated transcription factor), an established marker of melanocytes
[39] revealed no detectable SOX9 expression in human skin melanocytes in vivo (Fig. 1A-G).
In contrast, SOX10 was readily detectable in human melanocytes (S3A-S3B Fig.). Moreover,
while SOX10 was expressed in 100% of human giant congenital naevi, SOX9 expression was
not detected in the same set of patient samples (n = 17; (Fig. 1H; S3D Fig.); [9]). Likewise, all
samples of a melanoma tissue microarray composed of 56 primary melanoma biopsies revealed
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Figure 1. Differential expression of SOX10 and SOX9 in humanmelanocytes, human giant congenital naevi and humanmelanoma samples. A,
Scheme showing the localization of epidermal melanocytes (in red) in the human skin.B, C, Immunostaining for MITF (green, left panel) and SOX9 (red, right
panel) in the human skin demonstrating the lack of SOX9 expression in the epidermal melanocytes. Inserts show higher magnification images of MITF and
SOX9 immunostainings. Scale bars, 25 μm. D, Scheme showing the localization of melanocytes (in red) within the hair follicle. E, Immunostaining for MITF
(green) and SOX9 (red) in the human skin reveals the expression of SOX9 in the cells of outer root sheath but not in the MITF-positive melanoblasts/
melanocytes. Scale bar 100 μm. F, G, High magnification images of immunostaining for MITF and SOX9 in the upper part of human hair follicle (F) and the
follicular bulb (G). H, Analysis of SOX9 (red, left panel) and SOX10 (red, right panel) expression in the patients with human giant congenital naevi
demonstrates the lack of SOX9 expression in the SOX10-positive giant congenital naevi cells. Inserts show higher magnification. I, Representative examples
of immunostaining for SOX9 (green) and SOX10 (red) in a tissue microarray of primary melanoma samples are shown. J-K, Distribution of SOX10 vs. SOX9
expression in humanmelanoma (based on TCGA database). 334 melanoma patients were divided in two groups, namely SOX10 High/ SOX9 Low and
SOX10 Low / SOX9 high based on SOX10 and SOX9 expression levels. DP, dermal papilla; HF, hair follicle; M, melanocytes; ORS, outer root sheath. Scale
bars, 25 μm.
doi:10.1371/journal.pgen.1004877.g001
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strong SOX10 expression (Fig. 1I; [9]). SOX9 expression, however, was found in only 41% (23/
56) of the primary melanoma samples, in which it was expressed in a few scattered cells ac-
counting for less than 10% of all melanoma cells (Fig. 1I). In contrast, expression of SOX9 was
readily detectable in the epithelial lineage of normal skin as well as in basal cell carcinoma, an
epithelial skin cancer (Fig. 1E, F; S3C Fig.; [37,40]). To investigate the mRNA expression of
SOX10 and SOX9 in a large set of human melanoma samples, we used of the TCGA (The
Cancer Genome Atlas) database. Interestingly, the vast majority of human melanoma samples
displayed much higher SOX10 than SOX9 expression (Fig. 1J) and only very few samples were
characterized by a SOX9 high / SOX10 low expression pattern (Fig. 1K). Thus, SOX10 but not
SOX9 is prominently expressed in normal human melanocytes, human giant congenital naevi,
and primary melanoma.
SOX10 and SOX9 exhibit divergent functional roles in murine
melanocyte stem cells and hair pigmentation
To corroborate our findings in an experimentally amenable system, we extended the analysis
of Sox9 expression to mouse melanocytes, taking advantage of a previously described iDct-
GFP mouse line (Fig. 2A,B; [41]). Doxycycline-induced GFP-labelled melanocytes were isolat-
ed via fluorescence-activated cell sorting (FACS) and subjected to RNA-Seq analysis (Fig. 2A).
While Sox10, Mitf and Tyr were expressed at high levels (Sox10 reads were 1292, 1372, 1776
and 2488 at E15.5, E17.5, P1 and P7, respectively), the expression of Sox9 was extremely low
(Sox9 reads were 68, 65, 105 and 128 at E15.5, E17.5, P1 and P7, respectively). These data are
in accordance with earlier studies on Sox9 mRNA and protein expression in murine melano-
blasts and melanocytes [21,37] and suggest that in contrast to Sox10, Sox9 expression is virtual-
ly absent in the melanocytic lineage during mouse embryogenesis and postnatally.
Melanocyte stem cells are found in a specialized region of the hair follicle called bulge and
give rise to melanocyte progenitors and differentiated melanocytes [42]. The latter are located
in the lower hair follicle portion termed bulb, where they transfer pigment to the growing hair.
When melanocyte stem cells are functionally impaired, they fail to generate melanocytes,
which results in hair graying [43]. To further investigate the expression of Sox10 and Sox9 in
the melanocytic lineage of the mouse skin, we made use of Dct::LacZ transgenic mouse line
expressing LacZ driven by the dopachrome tautomerase (Dct) promoter that allows genetic
tracking of melanocyte stem cells and their derivatives in the hair follicle (Fig. 2C; [44]). Sox10
expression was detected in X-Gal-positive melanocyte stem cells located in the bulge region
(Fig. 2E, upper panels) as well as in differentiated melanocytes in the hair follicular bulb
(Fig. 2E, lower panels). Similarly to the situation in human melanocytes, immunostaining
with the specific anti-Sox9 antibody sc-20095 demonstrated absence of Sox9 expression in
X-Gal-positive melanocyte stem cells and their progeny (Fig. 2D, upper and lower panels).
Sox9 expression was restricted to cells of the epithelial lineage, namely the outer root sheath
and the epithelial stem cell compartment in the bulge area (Fig. 2D; S4 Fig.), in agreement with
previous reports [37,38,45].
To address the function of Sox10 and Sox9 in the melanocytic lineage in vivo, we condition-
ally ablated either Sox10 (Fig. 2H) or Sox9 (Fig. 2F) using Tyr-CreERT2 transgenic mice [46]
carrying floxed alleles of Sox10 [47] and Sox9 [27], respectively. Tamoxifen-induced homozy-
gous deletion of Sox10 in Sox10fl/fl Tyr-CreERT2mice resulted in progressive hair graying,
revealing an essential function of Sox10 for melanocyte stem cell homeostasis (Fig. 2I, [23]). In
contrast, homozygous deletion of Sox9 in the melanocytic lineage did not cause hair graying
even after a prolonged period after tamoxifen-induced gene deletion (Fig. 2G). Thus, these two
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Figure 2. Sox9 is not expressed in the mousemelanocytic lineage and is not functionally required for the maintenance of melanocyte stem cells
andmelanocytes in the postnatal skin. A, A schematic representation of the experimental strategy used to analyze the expression of Sox9, Sox10, Mitf
and Tyr genes in the melanocytic lineage in vivo. B, Results of RNA-seq analysis demonstrating high Sox10 and low Sox9 expression in melanocytic cells at
various stages of development. C, A schematic representation of the anatomical location of the melanocyte stem cells, melanoblasts and differentiated
melanocytes within the hair follicle in the mouse skin.D, X-Gal staining (blue) combined with Sox9 immunostaining (red) in skin sections of Dct::LacZmice
demonstrating the lack of the Sox9 expression in the melanocyte stem cells located in the bulge region of the hair follicle (upper panels) and in the
differentiated melanocytes located in the hair follicular bulb (lower panels). E, Skin sections of Dct::LacZmice stained for Sox10 (red) in combination with X-
Gal staining (blue) reveal the expression of Sox10 in the melanocyte stem cells (upper panels) as well as in the differentiated melanocytes (lower panels).
Dashed lines demarcate HFs. Insets show high magnification views. F-I, Experimental strategy used to analyze the effect of the lack of Sox9 (F) and Sox10
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closely related genes are not only differentially expressed but also play distinct roles in the biol-
ogy of melanocytes in vivo.
Sox10 and Sox9 are differentially expressed in mouse giant congenital
naevi and melanoma and exhibit functionally distinct roles in tumor
initiation
To functionally assess the role of SoxE factors in melanomagenesis, we first performed immu-
nohistochemical staining for Sox9 and Sox10 of giant congenital naevi formed in Tyr::NrasQ61K
mice and in melanoma derived from giant congenital naevi in Tyr::NrasQ61KInk4a−/−mice
[9,48]. In contrast to the widespread expression of Sox10 displayed by mouse naevi and mela-
noma tissue (Fig. 3B,D, [9]), immunostaining of both naevi and primary melanoma sections
did not reveal any detectable expression of Sox9 protein (Fig. 3A,C; S4B Fig.), consistent with
the data that we have obtained for human giant congenital naevi and melanoma (Fig. 1H-I).
Despite the lack of detectable Sox9 expression, low levels of Sox9 might be functionally impli-
cated in the formation of melanocytic lesions arising in Tyr::NrasQ61K mice. To address this
issue, we generated Tyr::NrasQ61K Sox9fl/fl Tyr-CreERT2mice and conditionally deleted both
Sox9 alleles by tamoxifen treatment of the mice (Fig. 3E). However, skin hyperpigmentation in-
duced by oncogenic NRas was not affected in Tyr::NrasQ61K Sox9fl/fl Tyr-CreERT2mice and
was comparable to that presented by their control Tyr::NrasQ61K littermates (Fig. 3F). These
data reveal that in contrast to Sox10 (Fig. 3G,H), Sox9 is not required for the formation of
melanocytic lesions.
Deletion of SOX10 in giant congenital naevus cells results in the
induction of SOX9 expression
To gain insight into the possible interplay between SOX10 and SOX9 during tumor progres-
sion, we quantified the expression levels of SOX10 and SOX9 in normal human melanocytes, in
cells from giant congenital naevi, and in a melanoma cell line (M010817; [49]) using quantita-
tive RT-PCR analysis (Fig. 4A-C). Notably, NRASQ61K-associated tumor progression was asso-
ciated with an increase in SOX10 expression (Fig. 4B). Cells from giant congenital naevi
showed a 5-fold increase in SOX10 expression when compared to normal melanocytes, while
M010817 melanoma cells displayed a 10-fold increase in SOX10 expression when compared to
normal melanocytes (Fig. 4B). In striking contrast to the increase in SOX10 expression, SOX9
expression levels were low in human melanocytes and further decreased with melanoma pro-
gression (Fig. 4C).
To assess whether the disparate expression of SOX9 and SOX10 is a general feature of
human melanoma samples, we analyzed the endogenous expression of these SOXE proteins in
a large set of human melanoma cell lines previously categorized into cells with proliferative
and invasive signatures, respectively [49]. Of note, all cell lines with a proliferative signature
were characterized by high SOX10/low SOX9 mRNA expression (Fig. 4D). However, many cell
lines with an invasive signature displayed the opposite expression pattern and showed low
SOX10/high SOX9 mRNA expression. These date were confirmed on the protein level by
Western blot analysis of several proliferative and invasive cell lines (Fig. 4E).
(H) expression in the mouse melanocytic lineage. Pictures of two representative mice at 6 months of age lacking Sox9 gene (G) and Sox10 gene (I)
demonstrating the effects on hair graying. Bg, bulge; HF, hair follicle; MSCs, melanocyte stem cells; Mo, months; E 15.5, embryonic day 15.5; P0, postnatal
day 0; SG, sebaceous gland. Scale bars, 25 μm.
doi:10.1371/journal.pgen.1004877.g002
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Figure 3. Mouse giant congenital naevi andmelanoma reveal no expression of Sox9. A-D, Immunostaining for Sox9 (A, C) and Sox10 (B, D) in the skin
sections of Tyr::NrasQ61K and Tyr::NrasQ61KINK4a−/−mice. E-H, Experimental strategy used to abrogate the expression of Sox9 (E) and Sox10 (G) in the
mouse melanocytic lineage. Pictures of two representative mice 1 year after tamoxifen injections reveal no reduction in the skin hyperpigmentation in Tyr::
NrasQ61KSox9fl/+Tyr-CreERT2mice as compared to their Tyr::NrasQ61K littermates (F) in contrast to a pronounced skin whitening observed upon Sox10 loss
(H). BF, bright field; HF, hair follicle; mo, months; P0, postnatal day 0. Scale bars, 25 μm.
doi:10.1371/journal.pgen.1004877.g003
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Figure 4. SOX10 knockdown results in elevated SOX9 expression in mouse and humanmelanocytes. A, Experimental design used to investigate the
level of SOX9 and SOX10 expression in vitro. Cultured human keratinocytes, melanocytes, cells derived from biopsies of patients with giant congential naevi
and melanoma cells (M010817 cell line) were subjected to RNA isolation and subsequent Q-RT-PCR analysis. Keratinocytes were used as a control. B, C,
Quantitative real-time PCR analysis showing the decline of SOX9 expression (C) and increase of SOX10 expression (B) that correlate with the acquisition of
malignant state by human NRASQ61K-mutated cells. Data are presented as the mean fold change and are normalized over levels found in melanocytes. D, E,
SOX10 and SOX9 expression in a large set of proliferative and invasive cell lines analysed by gene expression using microarrays (D) andWestern blot (E)
techniques. F, Experimental design used to deregulate SOX10 expression in human cells derived from the biopsy of a patient with NRASQ61K-mutated giant
congenital naevus.G, H, Quantitative real-time PCR analysis of SOX10 (G) and SOX9 (H) expression after the knockdown of SOX10. I, Experimental design
used to analyze the expression of Sox9 in the melanocytic lineage from Tyr::NrasQ61K and Tyr::NrasQ61K Sox10LacZ/+mice. K, L, Cells were isolated from the
trunk skin of Tyr::NrasQ61K and Tyr::NrasQ61K Sox10LacZ/+mice and stained for Melan-a and c-Kit antibodies. FACS-sorted cells were subsequently used for
the RNA isolation and quantitative real-time PCR with primers specific for the coding regions of Sox9 gene. Data are presented as the mean fold change and
are normalized to the control. Kerat, keratinocytes; M, melanocytes; Nev, naevus cells; Mel, melanoma cells; KD, knock down.
doi:10.1371/journal.pgen.1004877.g004
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Interestingly, an inverse correlation between SOX10 and SOX9 expression has previously
been observed in several systems, including cultured human melanocytes, where upon the in-
duction of differentiation, SOX10 levels were reduced concomitantly with an increase in SOX9
levels [32]. Thus, high expression of a given SoxE transcription factor might be causative for
reduced expression of the related SoxE factor. We therefore asked whether deregulation of
SOX10 leads to changes in SOX9 expression and found a significant upregulation of SOX9
mRNA expression upon SOX10 knockdown in human giant congenital naevus cells (Fig. 4F-H).
This is in analogy to the upregulation of SOX9 mRNA previously observed in melanoma cells
upon SOX10 knockdown [9]. Moreover, SOX10 knockdown also resulted in upregulation of
SOX9 protein levels in human melanoma cells (S5A Fig.). The combined data indicate that
SOX10 normally suppresses SOX9 expression in cells from melanocytic lesions.
To address whether the findings in human cells in vitro also apply to the in vivo situation in
mice, we isolated melanocytic progenitors using fluorescence-activated cell sorting (FACS)
from the skin of Tyr::NrasQ61K and Tyr::NrasQ61K Sox10LacZ/+ mice that lack one allele of Sox10
(Fig. 4I) and subsequently measured Sox9 expression levels using quantitative RT-PCR
(Fig. 4K, L). Elevated Sox10 levels mediated by oncogenic NRas in melanocytic cells from Tyr::
NrasQ61K mice [9] were associated with decreased Sox9 mRNA expression as compared to nor-
mal melanoblasts wild-type for NRas. However, reduced Sox10 levels brought about by Sox10
heterozygosity resulted in upregulation of Sox9 expression, as revealed by comparing cells
from Tyr::NrasQ61K with cells from Tyr::NrasQ61K Sox10LacZ/+ mice. Thus, in cells derived from
both human and mouse melanocytic lesions, reduced Sox10 levels were accompanied by elevat-
ed Sox9 expression.
SOX10 and SOX9 display antagonistic functions in melanoma cells
Based on our findings it is conceivable that increased levels of SOX9 might mediate at least
some of the anti-tumorigenic effects observed upon SOX10 loss-of-function in melanoma. To
address this hypothesis, we overexpressed SOX9 in human M010817 melanoma cells in vitro
and compared the gene expression profile of these cells with that of SOX10 knock-down mela-
noma cells, using the parental M010817 cell line as control [9]. Unsupervised hierarchical clus-
tering revealed that overexpression of SOX9 led to a gene expression profile closely resembling
the SOX10 knockdown-signature, which included in both conditions regulators of cell cycle
progression, apoptosis, and melanocytic and mesectodermal differentiation (Fig. 5A). Among
others, these data suggest that while SOX10 acts as an inhibitor of apoptosis in melanoma cells,
SOX9 elicits a proapoptotic response. Similarly, SOX10 and SOX9 appear to play antagonistic
functions in the regulation of the cell cycle, melanocytic differentiation, and mesectodermal
differentiation (Fig. 5A).
Notably, SOX9 overexpression resulted in decreased expression of a number of genes associ-
ated with melanocytic differentiation, such as MLANA, MITF, DCT, TYR, and importantly
SOX10. To confirm the downregulation of SOX10 upon SOX9 overexpression observed in mi-
croarray analysis (Fig. 5A) also on the protein level, we performed Western blot analysis and
observed a pronounced downregulation of SOX10 protein upon SOX9 overexpression in
human melanoma cell lines (Fig. 5B). Moreover, chromatin immunoprecipitation assays in
human melanoma M010817 cells indicated that SOX9 binds to the promoter of SOX10, sug-
gesting a direct regulation of the SOX10 gene by SOX9 (Fig. 5C). Thus, whereas SOX10 loss-of-
function leads to increased SOX9 expression (Fig. 4), high levels of SOX9 suppress SOX10 ex-
pression, revealing cross-regulatory interactions between these two transcription factors.
Next, we addressed whether the cross-regulation between SOX10 and SOX9 is functionally
relevant in human melanoma cells. To this end, we performed RNAi experiments to test
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whether interfering with SOX9 overexpression upon SOX10 knockdown could rescue
M010817 melanoma cells (Fig. 5D-F). Using two independent sets of siRNAs, the elevated
SOX9 levels observed in SOX10 knockdown cells were reverted below control levels by means
of concomitant SOX9 knockdown (Fig. 5E). Importantly, both SOX9 gain-of-function and
SOX10 knockdown promoted apoptosis (Fig. 5F; Fig. S5B). However, SOX10 knockdown cells
Figure 5. Experimental suppression of SOX9 expression rescues the effects of SOX10 deregulation in humanmelanoma cells. A, SOX9
overexpression in human melanoma cells closely resembles the gene expression signature of SOX10 knockdown as revealed by unsupervised hierarchical
clustering of control M010817 melanoma cells, SOX9 overexpressing M010817 cells and SOX10 knock down M010817 cells. Microarray gene expression
accession number: GSE37059. B, Western blot analysis showing that SOX10 expression is downregulated upon overexpression of SOX9 in two
independent humanmelanoma cell lines (A375 and M010817). C, Chromatin immunoprecipitation assay demonstrating the binding of SOX9 to the promoter
of SOX10 in humanmelanomaM010817 cells.D, E, Quantitative real-time PCR analysis of SOX10 (E) and SOX9 (F) expression after the knockdown of
SOX10 and after the double knockdown of SOX10 and SOX9 in M010817 cell line. F, Quantification of number of Annexin V-positive cells based on the
FACS analysis in the melanomaM010817 cells upon SOX9 KD, SOX10 KD or double SOX9/SOX10 KD. OE, overexpression; KD, knock down; ChIP,
chromatin immunoprecipitation; prom, promoter.
doi:10.1371/journal.pgen.1004877.g005
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were rescued when SOX9 expression was simultaneously downregulated, resulting in numbers
of apoptotic cells comparable to those found in control cells (number of Annexin V-positive
apoptotic M010817 cells: control, 9.95±0.9%; SOX10 siRNA #1, 19.96±0.13%; SOX10 siRNA
#2 18.8±0.49%; combination of SOX10 siRNA #1/SOX9 siRNA, 9.45±0.79%; combination of
SOX10 siRNA #2/SOX9 siRNA. 10.75±0.4%) (Fig. 5F; S5B Fig.). These data indicate that at
least in vitro, SOX9 plays a key role in mediating the cellular phenotype obtained in human
melanoma cells upon suppression of SOX10.
Deletion of Sox9 rescues the phenotype of Tyr::NrasQ61KSox10fl/+
Tyr-CreERT2 mice, restoring NrasQ61K-mediated naevus formation
As in human melanoma cells in vitro, reducing Sox10 levels in vivo elicits an anti-tumorigenic
effect, preventing melanocytic hyperplasia in Tyr::NrasQ61KSox10fl/+Tyr-CreERT2mice [9]. To
functionally test whether upregulation of Sox9 is the key factor accountable for the lack of hy-
perplasia in these mice in vivo, we performed simultaneous conditional ablation of both Sox10
and Sox9 genes in the Tyr::NrasQ61K mice (Fig. 6A, B). In agreement with our previous observa-
tions [9], the skin of the snout, paws and the back was noticeably lighter in color in Tyr::
NrasQ61KSox10fl/+Tyr-CreERT2mice as compared to their control Tyr::NrasQ61K littermates
(Fig. 6A, left and middle panels). In contrast, macroscopic examination of the skin of Tyr::
NrasQ61KSox10fl/+Sox9fl/flTyr-CreERT2 animals showed pronounced hyperpigmentation, a
hallmark of the skin phenotype found in Tyr::NrasQ61K mice (Fig. 6A, right panels). Thus, con-
ditional deletion of Sox9 rescued the effect of Sox10 haploinsufficiency in Tyr::NrasQ61K mice.
As shown in Fig. 2, conditional ablation of both alleles of Sox10 in the normal melanocytic
lineage using Tyr-CreERT2 resulted in loss of functional melanocytes and hair graying
(Fig. 2I). Likewise, homozygous deletion of Sox10 in Tyr::NrasQ61K mice not only prevented
NrasQ61K-stimulated skin hyperpigmentation, but also led to hair greying in these mice
(Fig. 6B, left panels). To determine whether these phenotypes involve Sox9 activity and wheth-
er, therefore, loss of Sox9 could rescue the effects of homozygous Sox10 deletion, we generated
Tyr::NrasQ61KSox10fl/flSox9fl/flTyr-CreERT2 animals. Surprisingly, loss of Sox9 in Sox10 homo-
zygous conditional knock-out animals efficiently restored skin hyperpigmentation as seen on
the snout and paws of Tyr::NrasQ61KSox10fl/flSox9fl/flTyr-CreERT2 animals when compared to
mice lacking Sox10 but not Sox9 in the melanocytic lineage (Fig. 6B, right panels).
We have previously demonstrated that skin hyperpigmentation in Tyr::NrasQ61K mice is
due to hyperplasia of ectopically located pigment cells emerging in the dermis, around the
upper part of the hair follicle [9]. To measure the degree of hyperpigmentation in Tyr::NrasQ61K
mice with conditional Sox10 deletion (heterozygous and homozygous) versus mice simulta-
neously lacking both Sox9 alleles and one or both Sox10 alleles in the melanocytic lineage, we
quantified the percentage of hair follicles associated with ectopically located melanocytic cells
in the back skin of these mouse lines. In Tyr::NrasQ61K mice, more than 90% of all hair follicles
displayed ectopic pigment cells (Fig. 6D). In contrast, in the absence of one or both alleles of
Sox10, there were almost no hair follicles with ectopic pigment cells, despite NrasQ61K expres-
sion (Fig. 6C, D). Strikingly, however, the percentage of hair follicles associated with ectopic
melanoblasts in Tyr::NrasQ61KSox10fl/+Sox9fl/flTyr-CreERT2 animals was reverted to numbers
similar to those found in Tyr::NrasQ61K mice (93±1.8% and 96±1%, respectively) (Fig. 6C, D).
Moreover, even in the absence of both Sox10 alleles, loss of Sox9 rescued the NrasQ61K–depen-
dent appearance of melanocytic cells found outside hair follicles (93.5±3%) (Fig. 6D). These
data reveal a key role of Sox9 in preventing melanoma initiation and provide novel insights
into the functional interplay between Sox10 and Sox9 during melanoma formation.
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Discussion
Our study identifies the structurally related transcription factors SOX10 and SOX9 as function-
ally antagonistic regulators of postnatal melanocyte and melanoma development. Although we
did not find SOX9 to be expressed in the melanocytic lineage when SOX10 is present, SOX9 ex-
pression becomes evident upon SOX10 inactivation in naevus and melanoma cells. In this con-
text, SOX9 appears to promote the major cellular processes induced by SOX10 loss-of-
function, namely stop of proliferation and apoptosis. Intriguingly, SOX9 and SOX10 are en-
gaged in a cross-regulatory feedback loop whereby SOX9, which is induced upon SOX10 inac-
tivation, itself suppresses SOX10, thus strengthening an anti-tumorigenic program.
In many cell lineages and tissues, SOX10 and SOX9 are co-expressed and functionally re-
dundant [50]. We propose that this is not the case in melanocytic cells and that SOX9, unlike
SOX10, is neither required for normal melanocyte stem cell homeostasis nor for formation of
congenital nevi and primary melanoma. Our findings disagree with some previously published
studies reporting SOX9 expression in the normal and tumor-associated melanocytic lineage
Figure 6. Homozygous deletion of Sox9 rescues the effects of Sox10 loss in Tyr::NrasQ61Kmice and restores hyperpigmentation in vivo. A, B,
Representative pictures of back skin, paws and snouts frommice of the indicated genotypes. C, D, Histological evaluation of the hyperpigmentation
phenotype in the skin. Haematoxylin and eosin staining of back skin (C) was followed by the quantification (D) of the percentage of hair follicles associated
with the hyperpigmentation. HF, hair follicle; H&E, haematoxylin and eosin.
doi:10.1371/journal.pgen.1004877.g006
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[32–34,36,51]. However, as we demonstrate here, most previously used anti-SOX9 antibodies
display cross-reactivity with SOX10, owing to the close relationship between these two SoxE
factors. Having identified anti-SOX10 and anti-SOX9 specific antibodies, we reveal virtually
exclusive expression patterns of these transcription factors in the normal human skin and in a
large set of melanoma biopsies and cell lines. While SOX10 expression is restricted to neural
crest derivatives, including melanoblasts, differentiated melanocytes, and virtually all human
naevus and melanoma biopsies tested (Fig. 1; S3 Fig.; [9], SOX9 expression in melanocytic cells
was restricted to few scattered cells in a subset of melanoma biopsies. In contrast, SOX9 was
strongly expressed in epithelial cells of the hair follicle, which are devoid of SOX10 expression.
In support of these data, Sox10 protein expression in the mouse skin is detected in vivo
throughout all stages of melanocyte development from stem cells to differentiated melanocytes
in the hair follicular bulb (Fig. 2). Mice lacking Sox10 in the melanocyte lineage display hair
graying, indicating that Sox10 is necessary for maintenance of melanocyte stem cells and com-
mitted melanoblasts [23] (Fig. 2). Likewise, Sox10 is required for the establishment of giant
congenital naevi as well as melanoma [9]. In contrast, murine Sox9 appeared not to be express-
ed in melanocytic cells of the normal skin, nevi, and primary melanoma, while it was readily
detectable in epithelial cells in accordance with previous reports [33,37,38]. Importantly, loss
of function analyses failed to reveal a crucial role of Sox9 in normal melanocytes, as conditional
deletion of Sox9 did not affect generation and long-term maintenance of melanocytes in vivo
and did not result in hair graying, a phenotype characteristic for the loss of Sox10. Likewise,
lack of Sox9 did not prevent emergence of melanocytic lesions induced by oncogenic NRasQ61K
(Fig. 3). These data demonstrate that Sox10 and Sox9 are not only expressed in different cellu-
lar compartments in the skin, but also play distinct roles in normal and
transformed melanocytes.
In cell types other than melanocytes Sox9 and Sox10 can act redundantly. For instance, in
oligodendroglial progenitors, concomitant expression of Sox9 can compensate for the loss of
Sox10 [52,53]. Similarly, in avian and Xenopus embryos, Sox9 and Sox10 are co-expressed in
premigratory neural crest cells and are both able to induce ectopic neural crest cell formation
upon forced expression in chicken neural tube [11,24,54]. In addition, the two factors are able
to cross-regulate each other at this early stage of neural crest formation. Interfering with Sox10
function leads to inhibition of Sox9 expression [55], suggesting that Sox10 is required for the
expression of Sox9 in pre-migratory neural crest. On the other hand, Sox9 overexpression in
Xenopus embryos leads to upregulation of Sox10 expression [24], suggesting that Sox9 can also
act upstream of Sox10. As development proceeds, however, Sox10 expression persists in the
trunk neural crest and is downregulated in cranial neural crest cells giving rise to mesectoder-
mal structures, while Sox9 expression is absent in trunk neural crest cells but present in the cra-
nial neural crest [24,26]. These divergent expression patterns are established by signaling
pathways differentially regulating transcription of Sox9 and Sox10, respectively. In particular,
TGFβ (transforming growth factor β) simultaneously triggers induction of Sox9 and reduction
of Sox10 expression [56]. Accordingly, mice lacking Sox10 display phenotypes that are distinct
from those obtained upon loss of Sox9 [13,54,56–58]. In particular, Sox10 but not Sox9 is ex-
pressed in and required for the generation of melanoblasts during mouse embryogenesis [13,
21]. Finally, in agreement with our expression studies on human skin, humans carrying muta-
tions in SOX9 display campomelic dysplasia affecting the skeleton and reproductive system but
not melanocytes, whereas patients with mutations in SOX10 often exhibit pigmentary anoma-
lies [20,50,59].
However, the divergent functions of Sox10 and Sox9 in the skin appear not to be simply due
to their differential expression patterns. Depending on the cellular context, these two transcrip-
tion factors can also elicit different responses in one and the same cell lineage rather than
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playing redundant roles. Studies in Xenopus embryos demonstrated that while expression of
Sox10 at the two-cell stage was sufficient to activate the expression of Trp-2 (Dct) and the in-
duction of melanocytic precursors, the expression of Sox9 failed to do so [24]. In mice, loss of
Sox9 promotes apoptosis and other phenotypes in neural crest cells, but Sox10 is maintained in
these cells and cannot rescue the Sox9-mutant phenotype [54]. Moreover, while Sox9 activates
the expression of genes involved in the induction of osteochondrogenesis in neural crest cells
in pharyngeal arches [26,28,60], Sox10 is involved in the specification of a glial and melanocy-
tic gene expression program [13]. In this context, Sox10 and Sox9 play antagonistic roles, in
that Sox9 promotes cells cycle exit and mesenchymal fates, while Sox10 activates proliferation
and suppresses mesenchymal fate acquisition [56]. Accordingly, Sox10 inactivation results in
induction of Sox9-dependent fates in postmigratory neural crest cells. This interplay between
Sox10 and Sox9 functions during normal neural crest development is highly reminiscent of our
findings in melanocytic lesions, where Sox10 also promotes proliferation and survival, while
Sox9 counteracts these cellular processes. Indeed, in human melanoma cells, loss of SOX10 not
only resulted in upregulation of SOX9 expression, but also in global transcriptional changes
highly similar to the changes observed upon SOX9 overexpression (Fig. 5), indicating that
these factors appear to play opposing functions in melanoma. Interestingly, a study by
Passeron et al. revealed that overexpression of SOX9 prevents melanoma formation [35] by in-
creasing the expression of the CDK inhibitor p21 and subsequent cell cycle arrest. Likewise, a
recent report by Pavan and colleagues established that the expression of p21 and p27 were in-
creased upon SOX10 knockdown [31]. Thus, our data might provide one explanation for the
anti-tumorigenic effect of SOX9, namely by downregulation of SOX10. This is in accordance
with our previously published results on the essential role of SOX10 for melanoma initiation
and progression [9]. Of note, the anti-tumorigenic effect elicited by suppressing SOX10 was
abolished by concomitant SOX9 inactivation both in human melanoma cells as well as in mice.
Thus, antagonistic SOX10/SOX9 constitutes a key node in the genetic network underlying
melanomagenesis. Nonetheless, it is conceivable that further cues mediate SOX10-pro- and
SOX9-anti-tumorigenic effects, respectively. Moreover, our data do not exclude a role of SOX9
at later stages of melanoma disease progression, in particular during metastasis formation by
invasive cells. Indeed, while we could attribute a SOX10 high/SOX9 low signature to prolifer-
ative human melanoma cell lines and to all human and murine melanoma tissues analyzed,
several human melanoma cell lines reported to display invasive features [49] exhibited SOX10
low/SOX9 high expression. Although this remains to be shown, these invasive cell lines with
SOX10 low/SOX9 high expression might have been established by capturing or inducing inva-
sive tumor cells that appear to be rather rare in biopsies of bulk tumor tissue. Likewise, apart
from experimentally reducing SOX10 levels, other stimuli such as UV exposure might also lead
to upregulation of SOX9 [51]. In any case, our discovery of the antagonistic interaction be-
tween SOX10 and SOX9, together with the further characterization of their mode of action in
melanoma cells, might not only provide new mechanistic insights into how SoxE group pro-
teins are regulated and act in the context of melanoma initiation and maintenance, but might
also point to novel strategies for melanoma therapies.
Materials and Methods
Human specimens
All analyses involving human skin, giant congenital naevi and melanoma tissue were per-
formed in accordance with the ethical committee in canton Zurich, Switzerland. TMA contain-
ing melanoma tissue was constructed as previously described [61].
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Mice
Tyr::NrasQ61K [48] were provided by F. Beermann (EPFL Lausanne, Switzerland). Dct-LacZ
mice were described previously [44]. Sox10fl/fl mice were described previously [47]. Sox9fl/fl
mice [27] were a kind gift from G. Scherer (Institute of Human Genetics, Freiburg, Germany).
Tyr-CreERT2 line [46] was provided by L. Chin (The University of Texas MD Anderson Can-
cer Center, Houston, Texas, USA). Rosa26-lacZmice were obtained from Jackson laboratory.
All animal experiments were performed in accordance with Swiss law and have been approved
by the veterinary authorities of Zurich.
Tamoxifen injections
Mice were subjected to intraperitoneal injections of tamoxifen (T5648, Sigma), diluted with the
mixture of ethanol and sunflower oil (1:9 ratio). Tamoxifen was injected for 5
consecutive days.
Histological analysis and immunohistochemistry
Immunohistochemistry on paraffin sections was performed as previously described [9]. Briefly,
skin samples were fixed in 4% buffered paraformaldehyde and embedded in paraffin. For
immunohistochemistry, antigen retrieval was performed in citrate buffer (pH 6.0) for 10 min-
utes at 110°C in HistoPro (Rapid Microwave Histoprocessor, Milestone, USA). The following
primary antibodies were used: anti-Sox10 (goat, 1:200, Santa Cruz Biotechnology, Santa Cruz,
CA), anti-Sox10 (mouse, 1:200, R&D), anti-Sox9 (rabbit, 1:100, sc-20095, Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-Sox9 (rabbit, 1:100, ab36748, Abcam), anti-Sox9 (M00006662,
Abnova), anti-Sox9 (AB5535, Millipore), anti-Sox9 (GTX 109661, GenTex), anti-MITF
(mouse, clone 6D3, 1:500) was a kind gift from Heinz Arnheiter (NIH, USA). Images were cap-
tured with a Leica DMI 6000B Microscope and using LAS AF (Leica Application Suite Ad-
vanced Fluorescence) software. For whole mount X-Gal staining, skin samples were fixed with
4% buffered paraformaldehyde, washed with PBS and subjected to X-Gal staining solution
overnight at 37°C. After several washing steps, tissue was paraffin embedded and sectioned.
5 μm thick sections were further counterstained with eosin solution and mounted.
RNA isolation, reverse transcription and quantitative PCR
Total RNA was isolated using Trizol according to manufacturer’s instructions (Invitrogen).
1 μg aliquots of RNA were reverse transcribed with Reverse Transcription System (Promega)
according to the manufacturer’s instructions. Data collection and analysis were performed by
ABI Viia7 Fast Real-Time PCR Systems (Applied Biosystems). Gene expression values of
averaged triplicate reactions were normalized to RPL28 expression levels. RPL28 primers are as
follows: 5’-GCAATTGGTTCCGCTACAAC-3’ and 5’-TGTTCTTGCGGATCATGTGT-3’.
The expression of SOX10 and SOX9 was measured using primers purchased from QIAGEN:
SOX10 (Hs_SOX10_1_SG); SOX9 (Hs_SOX9_1_SG).
Sequencing
Cells derived from patients with giant congenital naevi were sequenced for NRAS. Primers for
sequencing for Exon 1 (mutation G12) and Exon 2 (mutation Q61K) of NRAS gene were as
follows: NRAS_1F 5’-ATAGAAAGCTTTAAAGTACTG-3’ and NRAS_1R 5’-TTCCTTTAAT
ACAGAATATGG-3’, NRAS_2F 5’-CCCCTTACCCTCCACAC-3’ and NRAS_2R 5’-AACCT
AAAACCAACTCTTCCCA-3’.
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Cell culture and transfection assays
Silencing RNA (siRNA) transfection was carried out using INTERFERin transfection solution
according to the manufacturer’s protocol (Polyplus-transfection, Illkirch, France). Cells were
transfected with 10 nM of siRNA (Qiagen) for 96 hours before RNA was extracted or used for
FACS analysis. As control siRNA, the All-Star negative siRNA sequence (Qiagen) was used,
and gene-specific siRNAs targeting siSOX10 (SI00729414, SI00729421) and siSOX9
(SI00007595, SI00007609) were obtained from Qiagen. Transfection of DNA was carried using
JetPEI transfection solution according to the manufacturer’s protocol (Polyplus-transfection,
Illkirch, France). Cells were transfected with 1 ug of pCMV6-SOX9 (Origene SC321884) or
empty vector for 96 hours before RNA was extracted or used for FACS analysis.
Melanocyte FACS and RNA seq
Melanocytes were purified by FACS from doxycycline-treated iDct-GFP mice as previously
described [41]. Total RNA was prepared from FACS-sorted cell fractions containing GFP-
positive melanoblasts/melanocytes according to standard Illumina RNA-Seq paired-end
protocol and sequenced on the Illumina GAIIx to 80 bp per read.
Microarray analysis
Total RNA was isolated from melanoma cell cultures using TRIzol according to the manufac-
turer’s instructions (Invitrogen). Total RNA was amplified and biotin-labelled using the
Message Amp II-Biotin Enhanced aRNA Amplification Kit (Ambion, Austin, TX, USA). Bio-
tin-labelled RNA was hybridized to Affymetrix HG-U133 plus 2.0 oligonucleotide microarrays
following the manufacturer’s protocol (Affymetrix, Santa Clara, CA, USA). After hybridization,
microarrays were washed and stained using a GeneChip Fluidics Station 450 (Affymetrix) and
then scanned using a GeneChip Scanner 7G (Affymetrix). Raw data was processed by R using
the affycoretools package (RMA). Gene expression datasets for SOX10 knockdown were ob-
tained from NCBI GEO GSE37059. Gene expression analysis was performed by R using the
limma package. P-values were adjusted by FDR p-value adjustment. For melanoma cell lines
analysis (proliferative vs invasive): Normalized expression values were downloaded from
GSE4840 containing microarray data for twenty three melanoma cell cultures. Pearson’s prod-
uct moment correlation (r) was calculated for the SOX10 and SOX9 expression values across
all twenty three samples. P-value was determined from the t statistic calculated from r.
Flow cytometry and cell sorting
Skin tissue (from back skin) was digested with a mixture of Dispase (Roche) and Collagenase I
(Worthington) for 1 hour at 37°C and enzymatic reaction was stopped by addition of DMEM
media supplemented with 10%FCS as previously described [9]. Subsequently, single cell sus-
pension was filtered through 40 μm strainers (BD). For cell cycle analysis, Click-iT EdU
Alexa Fluor 647 Flow Cytometry Assay Kit (Invitrogen) was used. Cells were labeled with PI
according to manufacturer’s protocol and DNA content was measured using a BD FACSCanto
II flow cytometer (BD Biosciences) and a BD FACSDiva software (BD Biosciences). For mea-
surement of apoptosis, Annexin V-PE Apoptosis Detection Kit I (BD Pharmingen, 559763)
was used. FACSAria sorter and FACS DiVa software (BD Biosciences) were used for cell
sorting.
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Chromatin immunoprecipitation
ChIP analysis was performed as previously described [62]. Sox9 antibody was from Santa
Cruz Biotechnology (sc-20095, Santa Cruz Biotechnology). SOX10 promoter sequences were
amplified with forward primer (5’-CCTCTGCCTCGTGTGACTAC-3’) and reverse primer
(5’-TCCTGTCTGGAGTGGGCTG-3’).
Supporting Information
S1 Fig. Immunohistochemical analysis of the cross-reactivity of anti-Sox9 antibodies to
Sox10 in the mouse skin. A-D, Immunostaining for Sox9 (red) using different anti-Sox9 anti-
bodies, namely anti-Sox9 from Santa Cruz (A), Millipore (B), Abcam (C) and Abnova (D). E,
Summary of immunohistochemical analysis using anti-Sox9 antibodies from different sources.
ORS, outer rooth sheath; M, melanocytes.
(PPSX)
S2 Fig. Assessing the cross-reactivity of anti-SOX9 antibodies to SOX10. A-D, Western
blots demonstrating the cross-reactivity of anti-SOX9 antibodies (Abcam, Abnova and Milli-
pore) to SOX10 and specificity to SOX9 (A-D). E, A schematic illustration of the experiment
used to test anti-SOX9 antibodies. F-K, Western blots demonstrating the cross-reactivity of
anti-SOX9 antibodies using protein homogenates isolated from melanoma cells transfected
with either sh control or sh SOX10 vectors.
(PPTX)
S3 Fig. SOX10 and SOX9 expression in human melanocytic and epithelial lineages. A, A
schematic representation of the location of melanocytes in the hair follicular bulb. B, SOX10
expression in the hair follicular bulb. C, SOX9 expression in human basal cell carcinoma. D,
Analysis of the expression of SOX10 and SOX9 in the human giant congenital naevi (patient
H08 10533). Adjacent sections were stained with anti-SOX10 and anti-SOX9 antibodies. Note
the positive staining for SOX9 in the hair follicle. BCC, basal cell carcinoma; GCMN, giant con-
genital melanocytic naevi; M, melanocytes.
(PPTX)
S4 Fig. SOX9 is not expressed in the murine melanocytes and cells of giant congenital naevi
in the postnatal mouse skin. A, Bright field picture (left panel) showing the pigmented mela-
nocytes located in the hair follicular bulb. Immunostaining for SOX9 (red) demonstrating that
SOX9 is expressed in the epithelial cells of the hair follicle (outer root sheath) but not in the pig-
mented melanocytes. B, Immunostaining for Sox9 (red) demonstrating the expression of Sox9 in
the outer rooth sheath and the absence of Sox9 expression in the cells of giant congenital naevi in
Tyr::NrasQ61Kmouse. BF, bright field; HF, hair follicle, M, melanocytes; ORS, outer root sheath.
(PPTX)
S5 Fig. SOX9 and SOX10 play antagonistic roles in human melanoma cells. A, Western blot
analysis demonstrating that SOX9 expression is upregulated upon SOX10 knockdown in human
melanoma cell lines. B, FACS analysis of apoptosis inM010817 melanoma cell line. M010817 con-
trol cells, M010817 SOX10 KD cells, M010817 SOX9 OE andM010817 SOX10 KD SOX9KD cells
were analyzed for the number of Annexin V-positive cells. KD, knockdown; OE, overexpression.
(PPTX)
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